SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO.: SERIAL NO.: 10/718,948 39739-0029A							
DISCL	PTO-1449		APPLICANT: YING, et al.							
2005			FILING DATE: 11/20/03	GR	OUP: 1614					
CALLES TO SERVICE STATE OF THE PARTY OF THE		U.S	. PATENT DOCUMENTS			,				
EXAMINER'S INITIALS	PATENT NO. DATE		NAME	CLASS	SUBCLASS FILI		DATE			
		ļ		<del> </del>						
	<u> </u>	<u> </u>		<u> </u>			-			
	D. TENTANO	1	EIGN PATENT DOCUMENTS	1	SI TOCI ASS	TRANSLATION				
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	YES NO				
CH	WO 02/40468	05/23/02	PCT							
CH	WO 00/61576	10/19/00	PCT							
				ļ						
			Including Author, Title, Date, 1							
CH	·		of Experimental Pharmacology (	1990) 95:419	9-58.					
CH	<u> </u>		Biol (1990) 6:597-646.							
CH		Whitman, Genes Dev. 12:2445-62 (1998).								
CH	<u> </u>		d. 75:111-57 (2000).							
C#			uction by the TGF-β superfamily				•			
<u>CH</u>	·- <del></del>	<u>.</u>	signaling in renal disease" Am. S							
C#	Topper, J.N., "! factor" Trends	TGF-β in the co Cardiovasc. M	ardiovascular system: molecular led. 10:132-7 (2000).	mechanisms	of a context-spe	ecific gro	win			
Cit	Ițoh et al.,Signe	aling of transfo	rming growth factor-β family, Eu	ır. J. Biocher	n. 267:6954-67	(2000).				
CH	Xiao, R.P., Sci	STKE Oct 16:2	2001(104):RE15.							
CA	Port and Bristo	w, J. Mol. Cell	. Cardiol. 33:887-905 (2001).							
eil	Cross et al., Cit	rc. Res. 85:107	7-1084 (1999).	·						
CH		<del></del>	. Suppl. 1):E30-E35 (2002).							
CH	CH Bristow, Lancet 352 (Suppl. I) 8-14 (1998).									
EXAMINER	Carlin H	uynh	DATE CONSIDERED 4/10	0/07						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SV 2106412 v1 Attorney Docket No.: 39739-0029A

SHEET 2 OF 4

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.: SERIAL NO.: 10/718,948 39739-0029A						
		APPLICANT: YING, et al.						
			FILING DATE: 11/20/03	GR	OUP: 1614			
		U.S	S. PATENT DOCUMENTS					
EXAMINER'S	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
INITIALS								
		FOR	EIGN PATENT DOCUMENTS					
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIALS						YES	ИО	
	<u></u>			<u> </u>				
CH			Including Author, Title, Date, Pe	ertinent Pa	ges, Etc.)			
CH		Ligget S.B., J. Clin. Invest. 107:947-8 (2001).  Moniotte and Balligand, Cardiovasc. Drug. Rev. 2):19-26 (2002).						
CAF		McGraw et al., Am. J. Physiol. Lung Cell Mol. Physiol 281:L895-903 (2001).						
CH		MsGraw et al., Am. J. Physiol. Lung Cell. Mol. Physiol. 279:L379-89 (2000).						
CH		Johnson, M., Am. J. Respir. Crit. Care Med. 158:S146-S153 (1998).						
CH	Ligget et al, Reg 71-96, John Wild	Ligget et al, Regulation of Cellular Signal Transduction Pathways by Desensitization and Amplification, 71-96, John Wiley and Sons, New York, 1994; S. E. Mills, 2002, supra, and Johnson, M., 1998, supra.						
CH	Bristow et al., C	Bristow et al., Circ. Res. 59:297-309 (1986).						
Сн	Brodde and Micl	Brodde and Michel, Pharmacol. Rev. 51:651-690 (1999).						
CH	Ligget, J. Clin. I.	Ligget, J. Clin. Invest. 107:947-948 (2001).						
CH	Bristow, 1998, s	Bristow, 1998, supra; Bristow et al., N. Engl. J. Med. 307:205-211 (1982).						
CH	Nair et al., J. Ce	l Physiol. 16	54:232-239 (1995).		· ·			
eh	Lorita et al., Am.	J. Physiol. F.	feart. Circ. Physiol. 283:H1887-18	95 (2002).				
CF	Heath et al., J. P	hysiol. 512:7	79-791 (1998).					
CH	_ <del> </del>	Strader et al., J. Biol. Chem. 264:13572-13580 (1989).						
C H		lizuka et al., J. mol. Cel Cardiol. 26:435-440 (1994).						
C B		Rozankranz et al. (Am. J. Physiol. Heart. Circ. Physiol. 283:H1253-1262 (2002).						
CH		Henson et al., DNA Cell Biol. 19:757-763 (2000).						
CH		Gibson UEM, Heid CA and Williams PM. Genome Res. 6, 995-1001, 1996.						
CH EXAMINER (	Steinberg, Cir Ro	Steinberg, Cir Res. 85:1101-1111 (1999).  DATE CONSIDERED 4/10/07						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SV 2106412 v1 Attorney Docket No.: 39739-0029A

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.: SERIAL NO.: 10/718,948 39739-0029A APPLICANT: YING, et al.						
					U.	S. PATENT DOCUMENTS			
EXAMINER'S INITIALS	PATENT NO. DATE		NAME	CLASS	SUBCLASS	FILING DATE			
				<del> </del> -					
		FOF	REIGN PATENT DOCUMENTS		l	<u> </u>			
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
INITIALS						YES	NO		
		:							
	OTHER DO	CUMENTS	(Including Author, Title, Date, F	ertinent Pa	ges, Etc.)				
CH	Sabri et al., Cir	Sabri et al., Cir Res. 86:1047-1053 (2000).							
CH	Nogami et al. A	Nogami et al. Am. J. Physiol. 266:L187-191 (1994).							
CH	· Mak et al., Nau	nyn. Schmied	ebergs. Arch. Pharmacol. 362:520	-525 (2000)					
CH	Poncelet et al.,	Kidney Intern	national 56:1354-1365 (1999).						
CH	Zhao and Gever	end, <i>Biochen</i>	n. Biophys. Res. Commun. 294:319	-323 (2002)	•	<del> </del>			
C.H	Li et al., Circule	ation 98:II-14	14-II-160 (1998).						
CII	Hanoune and D	Hanoune and Defer, Annu. Rev. Pharmacol. Toxicol. 41:145-174 (2001).							
CH	Nair et al., J. Ce	l Physiol. 1	64:232-239 (1995).	·					
CH	Ziao et al., Circ	. Res. 85:109	2-1100 (1999).	-,			_		
ен	Minano et al., S	cience 264:5	82-586 (1994).		· 				
CH.	Liggett et al., C	irculation 10	1:1707-1714 (2000).						
cH	Communal et al	., Circulation	100:2210-2212 (1999).						
O.	Zhu et al., Proc	Zhu et al., Proc. Natl. Acad. Sci. USA 98:1607-1612 (2001).							
CH	Akhter et al., Pi	Akhter et al., Proc. Natl. Acad. Sci. USA 94:12100-12105 (1997).							
<i>ે</i> મ	Maurice et al.,	Maurice et al., J. Clin. Invest. 104:21-29 (1999).							
eH	Shah et al., Circ	Shah et al., Circulation 101:408-414 (2000).							
CA	Henson et al., D	Henson et al., DNA Cell Biol. 19:757-763 (2000).							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SV 2106412 v1 Attorney Docket No.: 39739-0029A

SHEET 4 OF 4

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO.: SERIAL NO.: 10/718,948 39739-0029A						
	PTO-1449		APPLICANT: YING, et al.						
		•	FILING DATE: 11/20/03	GROUP: 1614					
		U.	S. PATENT DOCUMENTS						
EXAMINER'S PATENT NO. DATE INITIALS			NAME	CLASS	SUBCLASS	FILING DATE			
		FOR	EIGN PATENT DOCUMENTS						
EXAMINER'S	PATENT NO. DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION			
INITIALS						YES	NO		
				<u></u>					
	OTHER DO	CUMENTS	(Including Author, Title, Date, P	ertinent Pa	ges, Etc.)				
CH	Gibson et al., G	enome Res. 6	, 995-1001, 1996.			_			
CH	Steinberg et al.,	Cir Res. 85:1	101-1111 (1999).						
CH	Sabri et al., Cir Res. 86:1047-1053 (2000).								
							_		
		<del></del> ,							
EVAMINED (	Carlinon	mh	DATE CONSIDERED 4/	10/07					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORM	摆	IR 3 0 2005	397	TY. DOCKET NO.: 39-0029A PLICANT: YING, et a ING DATE: 11/20/03 TENT DOCUMENTS NAME	al.	GRO	OUP: 1614		
INITIALS			+						<del></del>
			+				<del></del>		
		FOR	EIGN	PATENT DOCUMENT	s				
EXAMINER'S INITIALS	PATENT NO.	DATE		COUNTRY	CLA	.ASS	SUBCLASS	TRANSLATION YES NO	
CH	WO 00/12497 A2	March 9, 20	00	PCT					NO
		<u> </u>							
·									
			,						
	OTHER DO	OCUMENTS (	Inclu	ding Author, Title, Date,	Pertinen	t Pa	ges, Etc.)		
					<del> </del>				
					-				
		•		<del></del>					
EXAMINER	Carlie N.	umh	D	ATE CONSIDERED 4/	10/07				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-3-